A Detailed Understanding of the DREAMM-1 Study

14 Jan 2020 03:42 0
27
Targeted Oncology Download
1 0

Sagar Lonial, MD, FACP, reviews the design, efficacy, and safety of the DREAMM-1 study. He discusses primary and secondary end points, adverse events, and dose reduction for toxicity management.

For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/

Related of "A Detailed Understanding of the DREAMM-1 Study" Videos